Costs and outcomes of group B Streptococcus (GBS) screening strategies in France for prevention of neonatal early-onset GBS disease.

Paulo Martins¹, Theo Mantopoulos², Mindy Cheng³, Shivang Doshi³, Ines Messai⁴, Akriti Chahar⁵, Natalie Green⁶, Björn Vandewalle¹

¹IQVIA, Global Health Economics & Health Technology Assessment, Lisbon, Portugal.

²IQVIA, Global Health Economics & Health Technology Assessment, Athens, Greece.

³Cepheid, Value & Access, Sunnyvale, California, USA.

⁴Cepheid, Value & Access, Paris, France.

⁵IQVIA, Global Health Economics & Health Technology Assessment, Gurugram, India.

⁶IQVIA, Global Health Economics & Health Technology Assessment, London, UK.

PubMed DOI

Abstract

OBJECTIVE: Early-onset Group B Streptococcus (EOGBS) infection in neonates is prevented with intrapartum antibiotic prophylaxis (IAP). Traditionally, IAP candidates are identified via antepartum microbiological culture or clinical risk factors. While these strategies have reduced EOGBS incidence in many countries, some cases potentially preventable with IAP are missed. Point-of-care polymerase cha…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.